SMi's 10th annual Oncology Imaging for Drug Development conference will provide attendees with a comprehensive insight into the industry and its future. We will be considering the current landscape of personalised imaging within the field of oncology, as research suggests healthcare that is inherently more ‘personal’ is the way forward. In addition, this year’s event will explore current and future legislation and its impact on imaging. The use of imaging in clinical trials will also be examined and discussed together with the use of novel biomarkers. Event highlights include:•       Examine the challenges of multicentre imaging studies•       Two new sessions on audit methodologies and the central review from Perceptive Informatics and the US National Institute of Health•       Discuss case studies, challenges and opportunities in imaging guidelines featuring Novartis and GSK•       Gain an in-depth insight into the challenges of imaging in Europe•       Evaluate the value of imaging strategicallySpeaker Panel includes:•       Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics•       Lori Dodd, PhD, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, US National Institutes of Health•       Dr Marijn Vlaming, Research Scientist, TNO •       Prash Krishna, Global Clinical Leader - Oncology, Novartis•       Pallavi Chaturvedi, Imaging Project Manager, GSK Vesalius Imaging•       Francois Lassailly, Head of in Vivo Imaging, Cancer Research UK•       Dr Malcom Barratt-Johnson, Managing Director, PharmaMedic Consultancy Don’t miss the pre-conference workshop on: Pharmacokinetics, 11th March 2014, 08:30am-12:30pm | London, UK Led by Dr Marijn Vlaming, Research Scientist, TNO*Book before the 29 November and receive £300 early bird discount - booking before 1 January 2014 will give you £100 discount